ArticleVaccine2009
In situ adenovirus vaccination engages T effector cells against cancer.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 55 citations in OpenAlex.
- Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.Oncotarget · 2015Trial
- Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Trial
- Tumor cell membrane-based vaccines: A potential boost for cancer immunotherapy.Exploration (Beijing, China) · 2024Review
- Novel peptide-based vaccine targeting heat shock protein 90 induces effective antitumor immunity in a HER2+ breast cancer murine model.Journal for immunotherapy of cancer · 2022Article
- Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo.Molecular cancer therapeutics · 2022Article
- Oncolytic Adenoviruses for Cancer Therapy.International journal of molecular sciences · 2021Review
- Oncolytic Adenovirus: Prospects for Cancer Immunotherapy.Frontiers in microbiology · 2021Review
- Article
- Artificially cloaked viral nanovaccine for cancer immunotherapy.Nature communications · 2019Article
- Tumor Regression and Cure Depends on Sustained Th1 Responses.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2018Article
- Fighting Cancer with Mathematics and Viruses.Viruses · 2017Review
- Oncolytic Viral Therapy for Mesothelioma.Frontiers in oncology · 2017Review
- Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathways.Investigational new drugs · 2016Article
- Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.Biomedicines · 2016Review
- Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Antitumor effects of oncolytic adenovirus armed with PSA-IZ-CD40L fusion gene against prostate cancer.Gene therapy · 2014Article
- Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2/Neu inhibits the growth of salivary gland carcinoma cells.Journal of translational medicine · 2014Article
- Feasibility of Applying Helper-Dependent Adenoviral Vectors for Cancer Immunotherapy.Biomedicines · 2014Review
- Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
Abstract
The efficacy of cancer immunotherapy is limited because of central and peripheral immune tolerance towards tumor-antigens. We propose a novel approach based on the fact that the immune system has not evolved tolerance towards adenoviruses (Ads) and that Ads have not evolved efficient mechanisms for immune-escape. The host-response to intratumoral Ad-vector injection in mice that were immunologically tolerant to neu-positive syngeneic mammary-cancer (MMC) was investigated. Intratumoral injection with replication-deficient, transgene-devoid Ad induced immune responses at two different anatomical sites: the tumor-draining lymph nodes and the tumor microenvironment. The lymph nodes supported the generation of both neu- and Ad-specific T effector cells, while inside the tumor microenvironment only Ad-specific T cells expanded. Importantly, Ad-specific T cells were anti-tumor-reactive despite the presence of active regulatory T cell-mediated immune tolerance inside MMC tumors and anti-tumor efficacy of Ad was increased by pre-immunization against Ad despite the production of Ad-neutralizing antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.